Myriad Genetics Director Walter Phd Gilbert Unloads 30,000 Shares (MYGN)
Myriad Genetics (NASDAQ:MYGN) Director Walter Phd Gilbert unloaded 30,000 shares of the stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $37.58, for a total transaction of $1,127,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Myriad Genetics (NASDAQ:MYGN) traded down 0.64% on Wednesday, hitting $37.49. The stock had a trading volume of 2,529,309 shares. Myriad Genetics has a 1-year low of $20.02 and a 1-year high of $39.15. The stock’s 50-day moving average is $28.78 and its 200-day moving average is $26.4. The company has a market cap of $2.736 billion and a P/E ratio of 16.30.
Myriad Genetics (NASDAQ:MYGN) last announced its earnings results on Tuesday, February 4th. The company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.20. The company had revenue of $204.06 million for the quarter, compared to the consensus estimate of $176.02 million. During the same quarter in the previous year, the company posted $0.42 earnings per share. The company’s revenue for the quarter was up 36.9% on a year-over-year basis. On average, analysts predict that Myriad Genetics will post $2.16 earnings per share for the current fiscal year.
A number of research firms have recently commented on MYGN. Analysts at Credit Suisse upgraded shares of Myriad Genetics from an “underperform” rating to a “neutral” rating in a research note on Friday, February 7th. They now have a $29.00 price target on the stock. Separately, analysts at Ladenburg Thalmann downgraded shares of Myriad Genetics from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 5th. Finally, analysts at JMP Securities upgraded shares of Myriad Genetics from an “underperform” rating to a “market perform” rating in a research note on Wednesday, February 5th. They now have a $30.80 price target on the stock. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and three have assigned a buy rating to the company’s stock. Myriad Genetics currently has an average rating of “Hold” and an average price target of $27.77.
Myriad Genetics, Inc (NASDAQ:MYGN) is a molecular diagnostic company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.